Interferons (IFNs) have been shown to negatively regulate osteoclastogenesis. In a proteomic study to assess protein expression during osteoclastogenesis, we discovered that the expression level of Jak1 was significantly decreased during the early stage of osteoclast differentiation from mouse bone marrow macrophages (BMMs) upon stimulation with receptor activator of nuclear factor κB ligand (RANKL). RANKL induced Jak1 ubiquitination, and a proteasome inhibitor MG132 efficiently blocked the RANKL-induced degradation of Jak1. The expression level of Jak1 correlated with the susceptibility of osteoclast precursors to the negative regulatory effects of IFN-β on osteoclastogenesis, since pre-osteoclasts (pOCs) in which Jak1 expression is significantly reduced could proceed with osteoclastogenesis in the presence of IFN-β. Forced downregulation of Jak1 by small interfering RNA resulted in the efficient osteoclast differentiation of BMMs in the presence of inhibitory IFN-β, while overexpression of Jak1 in pOCs elicited IFN-β-dependent inhibition of osteoclastogenesis. Furthermore, we found that the IFN-β-induced inhibition of osteoclastogenesis required STAT3 downstream of Jak1. These data suggest that the regulation of Jak1 expression during osteoclast differentiation might serve as an intrinsic mechanism that determines osteoclast lineage commitment by modulating the negative regulation by IFN-β.
INTRODUCTION
Osteoclasts are multinucleated cells for bone resorption originated from the monocyte/macrophage lineage of hematopoietic cells. 1, 2 Osteoclast differentiation from its precursor is a multi-step process requiring both macrophage colony-stimulating factor (M-CSF) and receptor activator of nuclear factor κB ligand (RANKL). 3 The precursor cells first differentiate into mononuclear pre-osteoclasts (pOCs) and fuse to form multinucleated osteoclasts. M-CSF induces expression of RANKL receptor (RANK) as well as supports survival and proliferation of osteoclast precursors. 3 RANKL stimulates differentiation of precursors into osteoclasts by inducing the expression of osteoclastspecific genes including tartrate-resistant acid phosphatase (TRAP), cathepsin K, and calcitonin receptor. 1, 2, 4 RANKL is also required for the survival and activity of mature osteoclasts. 1, 2 Although more detailed mechanism is still expected to be unveiled, RANKL signaling includes the recruitment of TNF receptor-associated factors (TRAFs), the activation of transcription factors NF-κB, c-Fos, and NFATc1. It has been also demonstrated that the mitogen-activated protein kinase (MAPK) signaling pathways of ERK, JNK, and p38 as well as the phosphatidylinositol 3-kinase (PI 3-kinase)-Akt pathway are involved in RANKL-dependent osteoclast differentiation and function. [5] [6] [7] Considering the balance between the activities of osteoblast and osteoclast for bone homeostasis, it is conceivable that the negative regulators of osteoclastogenesis might be equally important as pro-osteoclastogenic factors for maintaining normal bone mass. 2 In this context, type I (IFN-α/β) and type II (IFN-γ) interferons have been shown to strongly inhibit osteoclast differentiation and function both in vivo and in vitro. IFN-γ accelerates proteasomal degradation of TRAF6, thereby abrogates RANKL-dependent signaling. 8 On the other hand, it has been shown that IFN-β inhibits the expression of cFos. 9 Recent findings that the members of suppressors of cytokine signaling (SOCS), which oppose Janus kinase (JAK)/STAT signaling induced by IFN-γ and IFN-β, reversed the inhibitory actions of the IFNs on osteoclastogenesis suggest the involvement of Jak signaling in the IFN-mediated inhibition of osteoclastogenesis. [10] [11] [12] However, the role of Jak kinases during osteoclastogenesis remains to be fully understood.
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Many of the skeletal diseases involve unregulated osteoclastogenesis leading to excessive bone resorption, which are frequently observed in osteoporosis, rheumatoid arthritis, periodontal diseases, cancer metastasis, and multiple myeloma. 2, 5 With increasing body of evidence that the IFN/Jak/STAT signaling pathway is involved in osteoclastogenesis, a more detailed understanding of the role for the components of this pathway during osteoclast differentiation may also provide insights into strategies for the intervention of bone destructive diseases.
In this study, utilizing a proteomic approach, we discovered that the expression level of Jak1 is significantly decreased during the early differentiation of bone marrow macrophages (BMMs) into pOCs upon RANKL stimulation via a ubiquitin-mediated proteasomal degradation mechanism. Thus, the inhibitory activity of IFN-β on osteoclast differentiation was limited to the early stage of osteoclastogenesis due to the lack of Jak1 in the later stages of differentiation. These results indicate the existence of a mode of regulation in osteoclast precursors that negates the negative regulatory effect of IFN on osteoclastogenesis by reducing Jak1 upon RANKL stimulation, which may in part explain the excessive osteoclastogenesis in rheumatoid arthritis despite high levels of IFN-β in synovium. Immunoprecipitation and immunoblotting-Immunoprecipitation and Western blotting were performed as described previously. 16 For experiments requiring multiple
MATERIALS AND METHODS

Animals and reagents-Five
Western blots using several phospho-specific antibodies, lysates were divided into same
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From 6 amounts and subjected to SDS-PAGE and immunoblotting individually. Each membrane was not stripped no more than three times. Although actin blots for loading control were done for each membrane, only one representative blot was shown. For the quantification of band intensities, developed films were scanned (PowerLook1100, Umax, Taiwan) and analyzed by TotalLab gel image analysis software (Nonlinear Dynamics, UK). The Jak1 protein expression was normalized using the actin band density of same lane to compensate for the protein loading.
Quantitative PCR analysis-Total RNAs were isolated using RNeasy kit (Qiagen, Osteoclast differentiation-Mouse bone marrow cells, isolated by flushing the marrow space of femora and tibiae, were incubated overnight on culture dishes in α-MEM supplemented with 10% FBS. After discarding adherent cells, cells were further incubated with 20 ng/ml M-CSF on Petri dishes. BMMs became adherent after 3-day culture and were used as osteoclast precursor cells. 17 Retroviral gene transfer-Retroviruses were packaged by transfecting pMX-IRES GFP-Jak1WT, -Jak1V658F, pSuper-retro-Jak1siRNA, and pSuper-retro-STAT3siRNA plasmids into Plat-E cells as described previously. 16 Retroviral infection was performed by incubating cells with virus-containing media with the addition of 10 µg/ml polybrene.
After overnight incubation, cells were either induced for osteoclast differentiation or used for signaling experiments. 16 For the siRNA experiments, successful down-regulation of proteins required 24~48 h of incubation after viral infection depending on the target. Statistical analysis-Student's t-test was used to determine the significance of differences between results.
RESULTS
Jak1 expression is decreased during bone marrow macrophage differentiation
into pre-osteoclasts-In an attempt to explore molecular mechanisms underlying macrophage differentiation into osteoclast, we utilized a proteomic approach to ascertain differentially expressed proteins during the early stage of osteoclast differentiation under the assumption that those differentially regulated proteins may have a role in osteoclast differentiation. After culturing BMMs in the presence of 30 ng/ml M-CSF alone or in combination with 200 ng/ml RANKL for 36 h, surface proteins were biotinylated, subjected to SDS-PAGE, and visualized ( 
Jak1 protein but not the mRNA expression level is affected by RANKL treatment-
BMMs were treated with M-CSF and 0~500 ng/ml RANKL for 24 h and cell lysates were analyzed for Jak1 expression by Western blotting ( Fig. 2A ). Jak1 expression was not altered by incubation with RANKL up to 10 ng/ml. However, 100 ng/ml or higher concentrations of RANKL significantly reduced Jak1 expression (left panel).
Densitometry results from three independent experiments showed that Jak1 expression was reduced to 72.3 ± 6.1 % and 50.7 ± 5.2 % of control after 100 and 500 ng/ml RANKL treatment, respectively (right panel). At 48 h after stimulation, more profound For personal use only. on October 3, 2017. by guest www.bloodjournal.org From 9 reduction of Jak1 expression was observed in cells treated with 100 or 500 ng/ml RANKL but not in BMMs treated with 10 ng/ml or less RANKL (data not shown). We next investigated the time-course of Jak1 expression levels upon RANKL stimulation. Fig. 2B show that the protein expression of Jak1 started to significantly decrease at 24 h after RANKL stimulation (left panel). When Jak1 band densities were analyzed by densitometry from three independent experiments (right panel), the mean Jak1 density at 24 h and 48 h after RANKL stimulation was 72.6 ± 6.7 % and 45.6 ± 7.4 % of control (0 h), respectively. A similar pattern of reduction in Jak1 expression level was also observed during the RANKL-induced osteoclastogenesis in RAW264.7 cells (Supplemental Fig. 1 ). However, Jak2 and Jak3 proteins were not down-regulated by RANKL in BMMs (Supplemental Fig. 2 ). The reduced expression of Jak1 and the formation of TRAP-positive multinuclear OCs seemed to correlate. Fig. 2C shows that the formation of OCs was minimal after the treatment of BMMs with 10 ng/ml RANKL for 72 h. However, 100 or 500 ng/ml RANKL, which reduced Jak1 expression significantly, induced efficient formation of OCs. Similarly, the formation of mononuclear pOCs measured at 48 h after stimulation also correlated with the RANKLdependent reduction of Jak1 expression (data not shown). Next we tested if Jak1 expression was regulated at the transcription level. BMMs were treated with 30 ng/ml M-CSF and 0~500 ng/ml RANKL for 48 h and total RNAs were isolated. Quantitative realtime polymerase chain reaction (PCR) analysis resulted in no significant difference in Jak1 mRNA levels during 48 h treatment of cells with 0~500 ng/ml RANKL (Fig. 2D) and during the course of 48 h incubation with 100 ng/ml RANKL (Fig. 2E) . Similarly, reverse transcription (RT)-PCR analysis showed no significant change in the Jak1 mRNA level (Supplemental Fig. 3 ).
Results in
RANKL induces ubiquitination of Jak1-Since Jak1 protein expression level was substantially reduced after RANKL stimulation without any significant change in the mRNA level, we hypothesized that Jak1 protein expression might be regulated by ubiquitin-mediated proteasomal degradation. To test this possibility, BMMs were grown in the presence of 30 ng/ml M-CSF plus 100 ng/ml RANKL and cell lysates were subjected to immunoprecipitation using Jak1-specific Ab followed by Western blotting with anti-ubiquitin Ab (Fig. 3A) . Upon stimulation with RANKL for 24 h and 48 h, extensively ubiquitinated protein bands having 130 kDa or higher molecular weights were immunoprecipitated with anti-Jak1 Ab, whereas Jak1 immunoprecipitates from control lysates (0 h) showed only slight level of basal ubiquitination. When the same membrane was stripped and reprobed with anti-Jak1 Ab, protein bands having higher molecular weight than that of the unmodified Jak1 (~130 kDa), corresponding to the ubiquitinated Jak1, appeared in 24 and 48 h stimulation samples, which were absent in control. To further confirm the Jak1 degradation via an ubiquitin-mediated proteasome pathway, BMMs were stimulated with RANKL for 48 h and a proteasome inhibitor MG132 was added during the final 4 h of incubation (Fig. 3B) . Western blotting revealed that the incubation of BMMs with the increasing concentrations of MG132 resulted in the increased level of Jak1 in cell lysates, suggesting that the proteasome-mediated degradation of Jak1 was blocked by MG132. Taken together, these results suggested that the decreased level of Jak1 following RANKL stimulation resulted from the RANKLinduced ubiquitination of Jak1 and subsequent proteasome-mediated degradation.
Jak1 expression on osteoclast precursors correlates with the IFN-β susceptibility
during osteoclast differentiation-We next examined the physiological significance of decreased Jak1 expression in osteoclast precursor cells during RANKL-induced osteoclastogenesis. Recently, it has been demonstrated that IFN-β exerts negative effects on RANKL-induced osteoclast formation, 9 which was confirmed in our study by culturing BMMs with RANKL in the presence of IFN-β (Fig. 4A) . The presence of IFN-β significantly reduced the formation of osteoclast as determined by the dramatically reduced formation of TRAP-positive large multinuclear cells after 3-day culture with RANKL ( Fig. 4B) . When an increasing concentration of IFN-β was used to inhibit osteoclast formation, as low as 2 U/ml IFN-β was sufficient to significantly inhibit osteoclastogenesis induced by 100 ng/ml RANKL (Fig. 4C ). The number of osteoclasts formed under the presence of 10 U/ml IFN-β for 3 days was less than 10% of those in the absence of IFN-β. Since the lack of Jak1 was known to be responsible for the unresponsiveness of cells to IFNs, 19 we postulated that pOCs, in which Jak1 expression is significantly reduced (Fig. 2) , might be resistant to the inhibition of osteoclastogenesis by IFN-β. To test this, BMMs were first cultured with RANKL for 2 days, treated with 10 U/ml IFN-β, and stained for TRAP activity at day 3 ( Fig. 4D ). As predicted, IFN-β had
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From no negative effect on osteoclast differentiation when added at 48 h after RANKL stimulation (Fig. 4E ). There was no significant difference in the osteoclast numbers with the tested concentrations of IFN-β (1~10 U/ml) (Fig. 4F) . The expression of type I IFN receptor was not affected by RANKL up to 500 ng/ml at 48 h after stimulation (data not shown). To further dissect the time point when BMMs cultured with RANKL become resistant to the negative effect of IFN-β, 10 U/ml IFN-β was added at different times after the addition of RANKL (Supplemental Fig. 4) . When IFN-β was added at the start of culture, there was significant reduction in the formation of osteoclasts. However, when IFN-β was added at 24 h or 48 h after RANKL addition, no significant decrease in the osteoclast number was observed. Furthermore, presence of IFN-β only for the first 24 h after RANKL stimulation was enough to inhibit osteoclastogenesis. Thus it seemed that the inhibitory action of IFN-β on osteoclastogenesis was limited to the early stage of osteoclast differentiation, when Jak1 expression is still intact.
Jak1 overexpression in pOCs elicits IFN-β-mediated inhibition of
osteoclastogenesis-Next we hypothesized that the forced expression of Jak1 into pOCs would induce these cells to be sensitive to the inhibitory effect of IFN-β. To test this, BMMs were first cultured in the presence of RANKL for 2 days and cells were infected with retroviruses harboring wild type Jak1 or constitutive-active Jak1 (Fig. 5A ). Fig. 5B shows that the infection of cells with viruses harboring wild type Jak1 (pMX-Jak1WT) or constitutive-active Jak1 (pMX-Jak1CA; Jak1V658F) 18 successfully increased Jak1 protein expression. After viral infection, pOCs were further differentiated into osteoclasts using RANKL in the presence of IFN-β. Uninfected and control virus-infected pOCs showed no difference in the numbers of differentiated osteoclasts in the presence or absence of IFN-β (Fig. 5C) . However, the overexpression of wild type Jak1 in pOCs sensitized pOCs to the anti-osteoclastogenic effect of IFN-β, leading to the significantly reduced formation of osteoclasts in the presence of IFN-β. Approximately 60% reduction in the numbers of TRAP-positive osteoclasts was observed (Fig. 5D) . Finally, overexpression of constitutive-active Jak1 inhibited osteoclast differentiation from pOCs independent of IFN treatment.
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Since the addition of a proteasome inhibitor MG132 significantly increased Jak1 expression (Fig. 3B) , the effect of IFN-β on osteoclastogenesis in the presence of MG132 was tested. BMMs were first cultured for 2 days with 100 ng/ml RANKL and 1 µM MG132 was added during the final 4 h of incubation (Supplemental Fig. 5A ). Although the addition of MG132 alone slightly decreased the osteoclast numbers, treatment of pOCs with MG132 re-sensitized cells to the inhibitory effect of IFN-β (Supplemental Fig. 5B ). While IFN-β at 10 U/ml concentration was ineffective to inhibit osteoclast formation when added at 48 h after RANKL stimulation, as low as 1 U/ml IFN-β significantly reduced the numbers of osteoclasts formed from the precursors pretreated with MG132. Treatment of cells with MG132 in our experimental scheme showed no cytotoxicity as tested by a tetrazolium-based assay (data not shown).
Jak1 knock-down protects BMMs from the IFN-β-mediated inhibition of
osteoclastogenesis-Since the overexpression of Jak1 in pOCs conferred IFN-β sensitiveness during RANKL-induced osteoclastogenesis, it was conversely expected that the knock-down of Jak1 in BMMs would protect these osteoclast precursors from the IFN-β-mediated inhibition of osteoclast differentiation. To test this, the expression of Jak1 in BMMs were down-regulated by introducing Jak1-specific small interfering RNA (Jak1siRNA) via retroviral infection (Fig. 6A) . Compared with the cells infected with control viruses, cells cultured with viruses harboring Jak1siRNA showed significantly reduced Jak1 expression (Fig. 6B) . These BMMs were then differentiated into osteoclasts using RANKL and the inhibitory effect of IFN-β on the osteoclastogenesis was examined. As shown in Fig. 6C , introduction of siRNA specific for Jak1 protected BMMs from the inhibitory effect of IFN-β on the RANKL-induced osteoclast differentiation, while cells infected with control viruses failed to differentiate into osteoclasts in the presence of IFN-β. When the increasing concentrations of IFN-β were used, 2 U/ml IFN-β was sufficient to significantly inhibit osteoclastogenesis in BMMs infected with control virus (Fig. 6D) . Similarly, IFN-β at 2 U/ml or higher concentrations significantly reduced the formation of TRAP-positive osteoclasts upon RANKL stimulation in Jak1siRNA virus-infected BMMs. However, consistently higher number of osteoclasts was observed in Jak1 knocked-down cells after IFN-β addition when Since Jak1 knock-down seemed to prominently hamper IFN-β-dependent STAT3 activation, the role of STAT3 during IFN-β-mediated inhibition of osteoclastogenesis was investigated. BMMs were infected with STAT3 siRNA viruses (Fig. 7C ) and the reduction of STAT3 expression was confirmed by Western blotting in control and STAT3 knocked-down BMMs (Fig. 7D ). When these BMMs were cultured with RANKL in the presence of IFN-β, STAT3 knocked-down BMMs were clearly protected from the inhibition of osteoclastogenesis by IFN-β ( Fig. 7E and Supplemental Fig. 6B ). While 
DISCUSSION
In the present study, we discovered that the expression of Jak1 is significantly reduced during the early stage of osteoclast differentiation by employing unbiased proteomic approach. Our results suggested that Jak1 expression is regulated via ubiquitinmediated proteasomal degradation upon RANKL stimulation. To our knowledge, this is the first evidence that directly shows the ubiquitination of Jak1 during any physiological process. Recently, it was shown that the ubiquitin-mediated proteasomal degradation regulates the members of Jak/STAT pathway. Jak2 was reported to be down-regulated via ubiquitin-proteasome pathway upon stimulation of cells by hormones and cytokines such as prolactin, IL-3, and IFN-γ. 20, 21 It was also demonstrated that STAT1 and STAT4
were ubiquitinated by ubiquitin E3 ligase SLIM. 22 Thus, our results add to a growing body of evidence that the ubiquitin-mediated degradation of Jak/STAT pathway proteins constitutes a novel mechanism regulating cellular events. At present, several questions remain to be answered regarding the RANKL-induced ubiquitination of Jak1, such as signaling pathways resulting in the Jak1 ubiquitination and the identity of ubiquitin E3
ligase.
The role of Jak1 is crucial in signaling events initiated by cytokines including IFNs. 19, 23 However, in spite of increasing evidence that IFN-mediated signaling is one of major mechanisms involved in the inhibition of osteoclastogenesis, the role of Jak1 Takayanagi et al. suggested that IFN-β might inhibit RANKL-induced osteoclastogenesis via a negative feedback mechanism since RANKL stimulated generation of endogenous IFN-β. 9 We could observe no significant increase in the RANKL-induced osteoclastogenesis in Jak1 knocked-down BMMs compared with control cells (Fig. 6) . Theses results can be at least partially explained by the fact that RANKL-induced expression of SOCS1 and SOCS3 were reduced in Jak1 knocked-down Fig. 8 ). Since SOCS proteins were reported to protect osteoclastogenesis from the inhibition by RANKL-induced endogenous IFN-β, 11, 12 it is possible that the effects of decreased Jak1 expression and decrease in the RANKLinduced SOCS proteins were balanced out.
STAT proteins have been suggested as mediators of negative signaling by IFNs during osteoclastogenesis. STAT1 played crucial role in IFN-mediated inhibition of osteoclastogenesis since STAT1-deficient precursor cells were resistant to the suppression of osteoclast differentiation by IFN-β and IFN-γ. 8, 9 Hematopoietic cellspecific STAT3-deficeint mice were described to show osteoporotic phenotype with increased number of osteoclasts, suggesting an involvement of this member of STAT family proteins in the negative regulation of osteoclastogenesis. 25 We observed significantly impaired STAT3 phosphorylation, and to a lesser extent, reduced STAT5 phosphorylation upon stimulation with IFN-β in Jak1 knocked-down BMMs as well as in pOCs compared with control BMMs (Fig. 7) . Furthermore, STAT3 knocked-down
BMMs could differentiate into osteoclasts in the presence of IFN-β. On the other hand, there was no significant difference in the IFN-β-induced tyrosine phosphorylation of STAT1 in Jak1 knocked-down BMMs and in pOCs compared with control BMMs (Fig.   7A and Supplemental Fig. 6A ). The overexpression of Tyk2 in BMMs resulted in more potent phosphorylation of STAT1 upon IFN-β stimulation (Supplemental Fig. 9 ), suggesting that Tyk2 might be playing a compensatory role to activate STAT1 when Jak1 is down-regulated. Thus, it is likely that STAT3 is playing important role downstream of Jak1 during IFN-β-mediated inhibition of osteoclastogenesis described in the present study. Although the exact mechanism by which STAT3 modulates osteoclastogenesis still needs to be unveiled, it was demonstrated that the expression of c-Fos was significantly increased in STAT3-deficient BMMs. 25 Since IFN-β is known to inhibit osteoclastogenesis by down-regulating c-Fos, 9 one possibility is that the reduced Jak1 expression and concomitant reduction in the STAT3 activity shown in the current study facilitates osteoclastogenesis by impeding the IFN-β-mediated decrease in c-Fos expression.
For To summarize, we observed the down-regulation of Jak1 resulted from the ubiquitin-mediated degradation during early osteoclast differentiation of BMMs induced by RANKL. The reduction in the Jak1 expression level correlated with the resistance to the anti-osteoclastogenic effect of IFN-β. The mechanism described in this study may be a part of the differentiation program that determines osteoclast lineage commitment. (MR) for 36 h and total cell lysates were subjected to SDS-PAGE followed by immunoblotting using anti-Jak1 antibody. Anti-actin blot was shown to ensure same loading between the two lanes. with 30 ng/ml M-CSF and 100 ng/ml RANKL for indicated times and total cell lysates were subjected to immunoprecipitation using anti-Jak1 antibody.
Immunoprecipitates were separated by SDS-PAGE and immunoblotted using anti-ubiquitin antibody. Blot was stripped and reprobed for Jak1. Jak1 and actin expression was also examined from a small portion of input lysates. 
